BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025

Reuters

05 Nov 2024

Nov 4 (Reuters) - Sana Biotechnology Inc :

* SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025

* SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES

* SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379

* SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION

* SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481550492"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481550492\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481550492?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481550492","market":"us","top_or_hot":-1,"title":"BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025","media":"Reuters","content":"<html><body><p>Nov 4 (Reuters) - Sana Biotechnology Inc   :</p><p>   * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025</p><p>   * SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES</p><p>   * SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379</p><p>   * SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION</p><p>   * SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-05 05:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Nov 4 (Reuters) - Sana Biotechnology Inc   :</p><p>   * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025</p><p>   * SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES</p><p>   * SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379</p><p>   * SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION</p><p>   * SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PACI.U","symbol_name":"PROOF Acquisition Corp I","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481550492","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481550492","pubTimestamp":1730756081,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 4  - Sana Biotechnology Inc   :   * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025   * SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES   * SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379   * SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION   * SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIALSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PACI.U":"PROOF Acquisition Corp I","SANA":"Sana Biotechnology, Inc.","BK4139":"生物科技"},"translate_title":"简介-Sana Biotechnology宣布更加关注1型糖尿病和B细胞介导的自身免疫性疾病，有可能在2024年和2025年提供多项研究的临床概念验证数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACI.U":1,"SANA":1},"content_text":"Nov 4 (Reuters) - Sana Biotechnology Inc   :   * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025   * SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES   * SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379   * SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION   * SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIALSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}